Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Vemakalant
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

794466-70-9

794466-70-9 structure

Name: Vernakalant
Chemical Name: (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
CAS Number: 794466-70-9
Molecular Formula: C₂₀H₃₁NO₄
Molecular Weight: 349.464
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Potassium Channel
Create Date: 2018-03-15 08:00:00
Modify Date: 2024-01-02 23:19:00
Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.IC50 value:Target:

Name	(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
Synonyms	(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-3-pyrrolidinol (1R,2R)-2-[(3R)-hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)cyclohexane Kynapid Vernakalant 3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)- Brinavess (1R-{2R-[2-(3,4-dimethoxyphenyl)-ethoxy]-cyclohex-2-yl})-pyrrolidin-3R-ol (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidin-3-ol RSD 1235 (3R)-1-{(1R,2R)-2-[2-(3,4-Dimethoxyphenyl)ethoxy]cyclohexyl}-3-pyrrolidinol 1R-(2R-(2-(3,4-dimethoxy-phenyl)-ethoxy)-cyclohexyl)-pyrrolidin-3R-ol Vernakalant [INN:BAN] UNII-9G468C8B13 cc-484 Vernakalant [INN] (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidinol

Description	Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.IC50 value:Target:
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> Potassium Channel Research Areas >> Cardiovascular Disease
References	[1]. Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50 -Issue 1 - pp 35-40. [2]. Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534 [3]. Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22. [4]. Blomstr?m-Lundqvist C, Blomstr?m P.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26. [5]. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Cardiovasc Drugs Ther. 2012 Apr;

Density	1.1±0.1 g/cm3
Boiling Point	479.0±45.0 °C at 760 mmHg
Molecular Formula	C₂₀H₃₁NO₄
Molecular Weight	349.464
Flash Point	243.5±28.7 °C
Exact Mass	349.225311
PSA	51.16000
LogP	2.40
Vapour Pressure	0.0±1.3 mmHg at 25°C
Index of Refraction	1.557

906802-36-6

~77%

794466-70-9

Literature: CARDIOME PHARMA CORP. Patent: WO2006/88525 A1, 2006 ; Location in patent: Page/Page column 118; 127-128 ;

1370354-69-0

794466-70-9

Literature: ALPHORA RESEARCH INC.; GORIN, Boris; DIXON, Craig Edward; OUDENES, Jan; BEJAN, Elena Valentina; KINSMAN, Aaron Cleveland Patent: WO2012/40846 A1, 2012 ; Location in patent: Page/Page column 22-23 ;

795281-92-4

794466-70-9

Literature: ASTELLAS PHARMA INC. Patent: WO2006/75778 A1, 2006 ; Location in patent: Page/Page column 26-28 ;

7417-21-2

794466-70-9

Literature: Limanto, John; Ashley, Eric R.; Yin, Jingjun; Beutner, Gregory L.; Grau, Brendan T.; Kassim, Amude M.; Kim, Mary M.; Klapars, Artis; Liu, Zhijian; Strotman, Hallena R.; Truppo, Matthew D. Organic Letters, 2014 , vol. 16, # 10 p. 2716 - 2719

822-87-7

794466-70-9

1360617-31-7

794466-70-9

795282-03-0

794466-70-9

Literature: CARDIOME PHARMA CORP.; ROTH, Carol, J. Patent: WO2006/138673 A2, 2006 ; Location in patent: Page/Page column 49; 74-75 ;

1370354-67-8

794466-70-9

Precursor 6
906802-36-6 795281-92-4 7417-21-2 822-87-7
1360617-31-7 795282-03-0
DownStream 0

794466-70-9	866525-68-0
748810-28-8	866455-16-5